NewGenIvf (NIVF) Research & Development (2024 - 2025)
NewGenIvf (NIVF) posted quarterly Research & Development of $1.7 million for Q4 2025, up 322.26% year-over-year from $398590.0 in Q4 2024, and up 999.03% quarter-over-quarter from -$187212.0 in Q3 2025.
NewGenIvf (NIVF) Research & Development (2024 - 2025) Analysis & Trends
NewGenIvf (NIVF) has reported Research & Development for 2 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development rose 322.26% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.8 million (changed N/A YoY), while the FY2025 annual figure was $1.2 million, up 476.17% from the prior year.
- Research & Development rose to $1.7 million in Q4 2025 per NIVF's latest filing, from -$187212.0 in the prior quarter.
- Across five years, Research & Development topped out at $1.7 million in Q4 2025 and bottomed at -$187212.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 88.19 Bn | 90.61 Bn | 15.19 Bn | - |
| 2 | Tenet Healthcare | 21.59 Bn | 21.56 Bn | 4.45 Bn | - |
| 3 | Encompass Health | 12.19 Bn | 12.86 Bn | 1.34 Bn | - |
| 4 | Davita | 11.52 Bn | 12.39 Bn | 1.16 Bn | - |
| 5 | Ensign | 10.59 Bn | 10.27 Bn | 306.24 Mn | - |
| 6 | Universal Health Services | 8.79 Bn | 8.72 Bn | 3.29 Bn | - |
| 7 | Pacs | 7.04 Bn | 6.88 Bn | 338.46 Mn | - |
| 8 | Chemed | 6.96 Bn | 6.92 Bn | 221.47 Mn | - |
| 9 | Concentra Group Holdings Parent | 4.52 Bn | 4.38 Bn | 192.10 Mn | - |
| 10 | NewGenIvf | 9,048.24 | -1.43 Mn | 524,025.00 | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.68 Mn |
| Sep 30, 2025 | -187,212.00 |
| Dec 31, 2024 | 398,590.00 |
| Sep 30, 2024 | -135,544.00 |